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Abstract 
Background: A critical problem in the clinical management of prostate cancer is that it is 
highly heterogeneous. Accurate prediction of individual cancer behaviour is therefore 
not achievable at the time of diagnosis leading to substantial overtreatment. It remains 
an enigma that, in contrast to breast cancer, unsupervised analyses of global expression 
profiles has not currently defined robust categories of prostate cancer with distinct 
clinical outcomes.  
Objective:  To devise a novel classification framework for human prostate cancer based 
on unsupervised mathematical approaches.  
Design, Setting, and Participants: Our analyses are based on the hypothesis that 
previous attempts to classify prostate cancer have been unsuccessful because individual 
samples of prostate cancer frequently have heterogeneous compositions. To address 
this issue we applied an unsupervised Bayesian procedure called Latent Process 
Decomposition to four independent prostate cancer transcriptome datasets obtained 
using samples from prostatectomy patients and containing between 78 and 182 
participants.  
Outcome Measurements and Statistical Analysis:  Biochemical failure was assessed 
using log-rank analysis and Cox regression analysis. 
Results and Limitations: Application of LPD identified a common process in all four 
independent datasets examined. Cancers assigned to this process (designated DESNT 
cancers) are characterized by low expression of a core set of 45 genes, many encoding 
proteins involved in the cytoskeleton machinery, ion transport and cell adhesion. For 
the three datasets with linked PSA failure data following prostatectomy, patients with 
DESNT cancer exhibited poor outcome relative to other patients (P = 2.65x10-5, 
P = 4.28x10-5, and P = 2.98x10-8). When these three datasets were combined the 
independent predictive value of DESNT membership was P = 1.61x10-7 compared to 
P = 1.00x10-5 for Gleason sum. A limitation of the study is that only prediction of PSA 
failure was examined.  
Conclusions: Our results demonstrate the existence of a novel poor prognosis category 
of human prostate cancer and will assist in the targeting of therapy, helping avoid 
treatment-associated morbidity in men with indolent disease.                                                                                    
 
Patient Summary: Prostate cancer, unlike breast cancer, does not have a robust 
classification framework. We propose that this failure has occurred because prostate 
cancer samples selected for analysis frequently have heterozygous compositions 
(individual samples are made up of many different parts that each have different 
characteristics). Applying a mathematical approach that can overcome this problem we 
identify a novel poor prognosis category of human prostate cancer called DESNT.  
Keywords: poor prognosis category; novel prostate cancer classification; DESNT prostate 
cancer; Latent Process Decomposition 
Words 3383  
 1. Introduction 
Risk categories based on PSA, Gleason score and Clinical Stage that predict PSA failure[1] 
underpin the treatment of localized prostate cancer, as illustrated, for example, by the  
UK National Institute for Health and Care Excellence guidelines[2].  Attempts to 
improved risk stratification have been made by the development of prognostic tests, 
such as Prolaris[3], Oncotype DX[4] and Decipher[5].  Most such expression-based 
prognostic signatures for prostate cancer have in common that they were derived using 
supervised steps, involving either comparisons of aggressive and non-aggressive 
disease[5,6] or the selection of genes representing specific biological functions[3,7,8]. 
Alternatively expression biomarkers may be linked to the presence of somatic copy 
number variations[9]. In contrast, for breast cancer, unsupervised analysis of 
trancriptome profiles, using approaches such as hierarchical clustering has identified 
robust disease categories that have distinct clinical outcomes and that require different 
treatment strategies[10].  
Our hypothesis is that completely unsupervised classification of prostate cancer based 
on transcriptome data has not been successful previously[9,11] because individual 
samples of prostate cancer can contain more than one contributing lineage[12,13] and 
frequently have heterogeneous compositions[14-16]. To test this idea, in the current 
study, we applied Latent Process Decomposition[17,18] (LPD). Based on the latent 
Dirichlet allocation method[19], LPD assesses the structure of a dataset in the absence 
of knowledge of clinical outcome or biological role[17]. In contrast to standard 
unsupervised clustering models (e.g. k-means and hierarchical clustering), individual 
cancers are not assigned to a single cluster: instead gene expression levels in each 
cancer are modeled via combinations of latent processes.  We previously used LPD to 
confirm the presence of basal and ERBB2 overexpressing categories in breast cancer 
datasets[17], and to show that, based on blood expression profiles, patients with 
advanced prostate cancer can be stratified into two clinically distinct groups[20].  
2. Materials and Methods 
 
2.1 The CancerMap dataset  
Fresh prostate cancer specimens were obtained and processed from a systematic series of 
patients who had undergone a prostatectomy at the Royal Marsden NHS Foundation Trust and 
Addenbrooke's Hospital, Cambridge as previously described[9,21,22].  The relevant local 
Research Ethics Committee approved was obtained. Expression profiles were determined and 
data was processed as previously described[22] using 1.0 Human Exon ST arrays (Affymetrix, 
Santa Clara, CA, USA) according to the manufacturer’s instructions. Data are available from the 
Gene Expression Omnibus: GSE (data to be released on publication).  CancerMap patients did 
not receive neo-adjuvant treatment.  
 
2.2 Additional Transcriptome Datasets 
We analysed five prostate cancer microarray datasets that will be referred to as: MSKCC, 
CancerMap, CamCap, Stephenson and Klein. The data used, platforms and location of clinical 
data are presented in Fig. 1b. Each dataset was obtained using samples from prostatectomy 
patients. CamCap dataset used in our study was produced combining Illumina HumanHT-12 V4.0 
expression beadchip (bead microarray) datasets (GEO: GSE70768 and GSE70769) obtained from 
two prostatectomy series (Cambridge and Stockholm) and consisted of 147 cancer and 73 
normal samples[9]. The CamCap and CancerMap datasets have in common 40 patients and thus 
are not independent. One RNAseq dataset consisting of 333 prostate cancers from The Cancer 
Genome Atlas was analysed which we refer to as TCGA[13]. The counts per gene supplied by 
TCGA were used. 
 
2.3 Latent Process Decomposition 
Latent process decomposition (LPD) [17,18], an unsupervised Bayesian approach, was used to 
classify samples into subgroups called processes. We selected the 500 probesets with greatest 
variance across the MSKCC dataset for use in LPD. These probesets map to 492 genes. For each 
dataset all probesets that map to these genes were used in LPD analyses (CancerMap: 507 
probesets, CamCap:483, Stephenson: 609).  
 LPD can objectively assess the most likely number of processes. We assessed the hold-
out validation log-likelihood of the data computed at various number of processes and used a 
combination of both the uniform (equivalent to a maximum likelihood approach) and non-
uniform (MAP approach) priors to choose the number of processes. For robustness, we 
restarted LPD 100 times with different seeds, for each dataset. Out of the 100 runs we selected 
a representative run that was used for subsequent analysis. The representative run, was the run 
with the survival log-rank p-value closest to the mode. For the Klein dataset, for which we do 
not have clinical data, we used the hold-out log-likelihood from LPD instead. 
 
2.4 Statistical Tests 
All statistical tests were performed in R version 3.2.2 (https://www.r-project.org/). Correlations 
between the expression profiles between two datasets for a particular gene set and sample 
subgroup were calculated as follows: 
1. For each gene we select one probeset at random; 
2. for each probeset we transformed its distribution across all samples to a standard normal 
distribution;  
3. the average expression for each probeset across the samples in the subgroup is 
determined, to obtain an expression profile for the subgroup.  
4. the Pearson’s correlation between the expression profiles of the subgroups in the two 
datasets is determined.  
Differentially expressed probesets were identified using a moderated t-test implemented in the 
limma R package[23]. Genes are considered significantly differentially expressed if the adjusted 
p-value was below 0.01 (p values adjusted using the False Discovery Rate).  
 Survival analyses were performed using Cox proportional hazards models, the log-rank 
test, and Kaplan-Meier estimator, with biochemical recurrence after prostatectomy as the end 
point. When several samples per patient were available, only the sample with the highest 
proportion of tumour tissue was used. Multivariate survival analyses were performed with the 
clinical covariates Gleason grade (≤7 and >7), pathological stage (T1/T2 and T3/T4) and PSA 
levels (≤10 and >10). We modelled the variables that did not satisfy the proportional hazards 
assumption (T-stage in MSKCC), as a product of the variable with the heavyside function: 
  
where t0 is a time threshold. The multiplication of a predictor with the heavyside function, 
divides the predictor into time intervals for which the extended Cox model computes different 
hazard ratios. Before carrying out multivariate analyses we assessed collinearity between 
the DESNT predictor and the other traditional indicators. To do this we calculated the 
variance inflation factor (VIF) for each covariate in each model. VIF varied between 
1.005241 and 1.461661, suggesting a very weak correlation between the predictors. 
 
2.5 Driving an optimal predictor of DESNT membership 
To derive an optimal predictor of DESNT membership the datasets were prepared so that they 
were comparable: probes were only retained if the associated gene was found in every 
microarray platform, only one randomly chosen probe was retained per gene and the batch 
effects adjusted using the ComBat algorithm[24]. The MSKCC dataset was used as the training 
set and other datasets as test sets.  Gene selection was performed using regularized general 
linear model approach (LASSO) implemented in the glmnet R package[25], starting with all genes 
that were significantly up or down regulated in DESNT in at least two of the total of five 
microarray dataset (1669 genes). LASSO was run 100 times and only genes that were selected in 
at least 25% of runs were retained. The optimal predictor was then derived using the random 
forest model[26] implemented in the randomForest R package[27]. Default parameters were 
used, apart from the number of trees were set to 10001 and the class size imbalance was 
adjusted for by down-sampling the majority class to the frequency of the minority class 
 
 
3. Results  
3.1 Identification of the DESNT cancer category 
Four independent transcriptome datasets (designated MSKCC[11], CancerMap, 
Klein[28], and Stephenson[29], Fig. 1b) obtained from prostatectomy specimens were 
analyzed. LPD was performed using between 3 and 8 underlying latent processes 
contributing to the overall expression profile as indicated from log-likelihood plots (Fig. 
1b, Supplemental Fig. 1). Following the independent decomposition of each dataset, 
cancers were assigned to individual processes based on their highest pi value yielding 
the results shown in Fig. 1a and Supplemental Fig. 2. pi is the contribution of each 
process “i" to the expression profile of an individual cancer: sum of pi over all 
processes=1.   
 
Searching for relationships between the decompositions, a single process was identified 
that, based on correlations of gene expression levels, appeared to be common across all 
four datasets (Fig. 1c). To further investigate this association, for each dataset, we 
identified genes that were expressed at significantly lower or higher levels (P < 0.01 
after correction for False Discovery Rate) in the cancers assigned to this process 
compared to all other cancers from the same dataset. This unveiled a shared set of 45 
genes, all with lower expression (Fig. 2a, Supplemental Table 1). Many of the proteins 
encoded by these 45 core genes are components of the cytoskeleton or regulate its 
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dynamics, while others are involved in cell adhesion and ion transport (Fig. 2b). Eleven 
of the 45 genes were members of published prognostic signatures for prostate cancer 
(Fig. 2c, Supplemental Data File 1). For example MYLK, ACTG2, and CNN1 are down-
regulated in a signature for cancer metastasis[30], while lower expression of  TPM2 is 
associated with poorer outcome as part of the Oncotype DX signature[4]. The cancers 
assigned to this common process are referred to as “DESNT” (latin DEScenduNT, they 
descend).   
 
3.2 Patients with DESNT cancers exhibit poor prognosis 
Using linked clinical data available for the MSKCC expression dataset we found that 
patients with DESNT cancer exhibited poor outcome when compared to patients 
assigned to other processes (P = 2.65x10-5, Log-rank test, Fig. 1d). Validation was 
provided in two further datasets where PSA failure data following prostatectomy were 
available (Fig. 1d): for both the Stephenson and CancerMap datasets patients with 
DESNT cancer exhibited poor outcome (P = 4.28x10-5 and P = 2.98x10-8 respectively). The 
number of cancers in each group is indicated in the bottom right corner of each Kaplan-
Meier plot. The number of patients with PSA failure is indicated in parentheses. In 
multivariate analysis, including Gleason sum, Stage and PSA, assignment as a DESNT 
cancer was an independent predictor of poor outcome in the Stephenson and 
CancerMap datasets (P = 1.83x10-4 and P = 3.66x10-3, Cox regression model) but not in 
the MSKCC dataset (P = 0.327) (Table 1, Supplemental Fig. 3). When the three datasets 
were combined the independent predictive value of DESNT membership was 
P = 1.61x10-7 (Supplemental Fig. 3), compared to P = 1.00x10-5 for Gleason sum. 
Including surgical margin status in the multivariate analysis had little influence on these 
values giving P =3.63x10-7 for DESNT compared to P = 1.80x10-5 for Gleason Sum. The 
combined multivariate model is a significant improvement over a baseline Cox 
proportional hazard ratio model containing Gleason, PSA and Clinical Stage (p=9.528x10-
7; likelihood ratio test). The poor prognosis DESNT process was also identified in the 
CamCap dataset[9] (Table 1, Supplemental Fig. 3 and 4), which was excluded from the 
above analysis because it was not independent: there is a substantial overlap with 
cancers included in CancerMap (Fig. 1b).  
 
3.3  A random forest classifier for identifying DESNT cancer 
We wished to develop a classifier that, unlike LPD, was not computer processing 
intensive and that could be applied both to a wider range of datasets and to individual 
cancers. 1669 genes with significantly altered expression between DESNT and non-
DESNT cancers in at least two datasets were selected for analysis. A LASSO logistic 
regression model was used to identify genes that were the best predictors of DESNT 
membership in the MSKCC dataset leading to the selection of a set of 20 genes 
(Supplemental Table 2), which had a one gene overlap (ACTG2) to the 45 genes with 
significantly lower expression in DESNT cancers. Using random forest (RF) classification 
these 20 genes provided high specificity and sensitivity for predicting that individual 
cancers were DESNT in both the MSKCC training dataset and in three validation datasets 
(Supplemental Fig. 5). For the two validation datasets (Stephenson and CancerMap) 
with linked PSA failure data the predicted cancer subgroup exhibited poorer clinical 
outcome in both univariate and multivariate analyses, in agreement with the results 
observed using LPD (Table 1, Fig. 3).  
 
3.4 DESNT cancers in the The Cancer Genome Atlas dataset 
When RF classification was applied to RNAseq data from 333 prostate cancers described 
by The Cancer Genome Atlas (TCGA)[13] a patient subgroup was identified that was 
confirmed as DESNT based on: (i) correlations of gene expression levels with DESNT 
cancer groups in other datasets (Supplemental Fig 6); (ii) demonstration of overlaps of 
differentially expressed genes between DESNT and non-DESNT cancers with the core 
down-regulated gene set (45/45 genes); and (iii) its poorer clinical outcome based on 
PSA failure (P = 5.4x10-4) compared to non-DESNT patients (Table 1, Fig. 3e). 
 
For the TCGA dataset, we failed to find correlations between assignment as a DESNT 
cancer and the presence of any specific genetic alteration (P > 0.05 after correction for 
False Discovery Rate, χ² test, Fig. 4).  Of particular note there was no correlation to ETS-
gene status (P, = 0.136, χ² test, Fig. 4). A lack of correlation between DESNT cancers and 
ERG-gene rearrangement, determined using the fluorescence in situ hybridization 
break-apart assay[31], was confirmed using CancerMap samples (LPD-DESNT, P = 0.549; 
RF-DESNT, P = 0.2623, χ² test: DESNT cancers identified by LPD and by RF approaches 
are referred to respectively as LPD-DESNT and RF-DESNT). These observations are 
consistent with the lack of correlation between ERG status and clinical outcome[32], 
although different views on the relationship between ERG-gene status and clinical 
outcome have been expressed[33].  Since ETS-gene alteration, found in around half of 
prostate cancers[13,31], is considered to be an early step in prostate cancer 
development[15,34]  it is likely that changes involved in the generation of DESNT cancer 
represent a later event that is common to both ETS-positive and ETS-negative cancers. 
For RF-DESNT cancers in the TGCA series many of the 45 core genes exhibited altered 
levels of CpG gene methylation compared to non-RF-DESNT cancers (Supplemental 
Table 3) suggesting a possible role in controlling gene expression.  Supporting this idea, 
for sixteen of the 45 core genes epigenetic down-regulation in human cancer has been 
previously reported, including six genes in prostate cancer (CLU, DPYSL3, GSTP1, 
KCNMA1, SNAI2, and SVIL) (Fig 2b, Supplemental Table 1). CpG methylation of five of 
the genes (FBLN1, GPX3, GSTP1, KCNMA1, TIMP3) has previously been linked to cancer 
aggression.  
 
4. Discussion 
Evidence from The European Randomized study of Screening for Prostate Cancer 
demonstrates that PSA screening can reduce mortality from prostate cancer by 21%[35]. 
However, a critical problem is that the progression of prostate cancer is highly 
heterogeneous[36,37] and PSA screening leads to the detection of up to 50% of cancers 
that are clinically irrelevant[38,39]: that is cancers that would never have caused 
symptoms in a man’s lifetime in the absence of screening. Unsupervised analyses of 
breast cancer datasets using hierarchical clustering previously revealed the existence 
basal, ERBB2-overexpressing and luminal cancer categories[10]. This mathematical 
approach has not proven successful when applied to prostate cancer microarray 
datasets[9,11]. However in our study the use of LPD, an unsupervised method that takes 
into account the issue of cancer heterogeneity, has revealed the existence of a novel 
category of prostate cancer, designated DESNT, common across all datasets. The 
subsequent linking to clinical data revealed that DESNT cancers exhibit poor prognosis.  
It was notable that membership of the DESNT cancer groups was not an independent 
predictor of clinical outcome in the MSKCC dataset. It is possible that the difference may 
simply reflect statistical variation since the size of the DESNT group in several datasets 
was small (MSKCC, 13%; CancerMap, 8%; Stephenson, 31%; Klein, 23%). Critically, 
however, when the datasets with linked clinical data were combined DESNT 
membership remained an independent predictor of clinical outcome. We failed to 
detect systematic differences between MSKCC and other datasets used in multivariate 
analyses (Supplemental Fig. 3h). 
 
We have not, in this study, investigated the biological function and mechanisms of 
alterations of expression of the 45 core genes. However gene down-regulation 
mediated by CpG methylation is well documented in human cancer, as is the association 
of CpG methylation of single genes with aggressive cancer behavior (Supplemental Table 
1).  The results found for DESNT cancers are consistent with these observations, but 
would suggest that it is the combine under expression of multiple genes that represents 
a critical determinant of cancer progression and aggression. Several of the genes found 
to have lower expression in DESNT cancer (ACTA2, CNN1, LMOD1) encode proteins 
primarily expressed in smooth muscle cells or myofibroblast, indicative of an altered 
tumour-stromal environment.  We failed to find a correlation between stromal content 
and clinical outcome in the CamCap and CancerMap datasets (Fig. 2). However this does 
not exclude the possibility that DESNT cancers themselves may have lower stromal 
content, in part explaining the lower expression of these genes.  
Other under-expressed genes encode components of the actin cytoskeleton or regulate 
its dynamics (e.g. MLCK, MYL9, ACTN1, and TNS1). Increased malignancy may correlate 
with increased cell migratory behaviour, which in turn can involve deployment of 
particular types of cell adhesion and cytoskeletal machinery[40].  A high dependency on 
actomyosin contractility is recognised as a hallmark of amoeboid movement. Down-
regulation of these genes in DESNT cancers would argue against its involvement. The 
lower expression of focal adhesion components such as integrin α5 (ITGA5), vinculin 
(VCL) and integrin-linked kinase (ILK), would also argue against involvement of 
"mesenchymal" type migration, which is dependent on these classes of genes[40].  It is 
thus possible that the observed alterations may support involvement of collective 
migration or expansive growth phenotypes[40]. 
 
Notably, we failed to find any relationship between DESNT cancers and either CNV (copy 
number variant) signatures (Lalonde et al. and Ross-Adams et al. in Fig. 2c) or DNA 
repair gene alterations (Fig. 4).  Assignment of cancers within the DESNT classification 
framework together with the use of standard clinical indicators (Stage, Gleason sum, 
PSA), CNV signatures[11], expression biomarkers such as Prolaris[3], Decipher[5], and 
Oncotype DX[4] identified in supervised analyses and urine biomarkers[41], should 
significantly enhance the ability identify patients whose cancers should be targeted by 
radical therapies, avoiding the side effects of treatment, including impotence, in men 
with non-aggressive disease. In future studies we are focusing on the development of 
both LPD and RF based tests that can be used to detect DESNT cancer in biopsy tissue in 
a clinical setting. 
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FIGURES AND TABLES 
 
Figure 1. Latent Process Decomposition (LPD), gene correlations and clinical outcome. a, LPD analysis of 
Affymetrix expression data from the MSKCC datasets divided the samples into eight processes, each 
represented here by a bar chart. Samples are represented in all eight processes and height of each bar 
corresponds to the proportion (pi) of the signature that can be assigned to each LPD process. Samples are 
assigned to the LPD group in which they exhibit the highest value of pi. LPD was performed using the 500 
gene probes with the greatest variation in expression between samples in the MSKCC dataset. The 
process containing DESNT cancers is indicated. b, List of datasets used in LPD analysis. The unique number 
of primary cancer and normal specimens used in LPD are indicated. FF, fresh frozen specimen; FFPE, 
formalin-fixed paraffin embedded specimen. The CancerMap and CamCap were not independent having 
40 cancers in common. Clinical and molecular details for the CancerMap dataset are given in 
Supplemental Table 4 and Supplemental Data File 2. Clinical details for samples from other datasets used 
in this study can be found in Supplemental Data File 3.  c, Correlations of average levels of gene 
expression between cancers designated as DESNT. All six comparisons for the MSKCC, CancerMap, 
Stephenson and Klein datasets are shown. The expression levels of each gene have been normalised 
across all samples to mean 0 and standard deviation 1. d, Kaplan-Meier PSA failure plots for the MSKCC, 
CancerMap and Stephenson datasets.  
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Figure 2. Genes commonly down-regulated in DESNT poor prognosis prostate cancer. a, Number of 
genes with significantly altered expression in DESNT cancers compared to non-DESNT cancers (P<0.01 
after correction for False Discovery Rate).  45 genes had lower expression in DESNT cancers in all four 
expression microarray datasets, based on a stringency requirement of being down-regulated in at least 80 
of 100 independent LPD runs. b,  List of the 45 genes according to biological grouping. Previous published 
evidence is represented as superscripts and the supporting references are provided in Supplemental Table 
1. Encoded protein functions are shown in Supplemental Table 5.  Although some of the 45 genes are 
preferentially expressed in stromal tissue we found no correlation between stromal content and clinical 
outcome in both the CancerMap and CamCap patient series, where data on cellular composition were 
available. When patients were stratified into two groups (above and below median stromal content) 
Kaplan-Meier plots failed to show outcome difference for both the CancerMap (Log-rank test, p=0.159) 
and CamCap (p=0.261) patient series.  c. Relationship between the genes in published poor prognosis 
signatures for prostate cancer and the DESNT classification for human prostate cancer, represented as a 
circos plot. Links to the 45 commonly down-regulated genes are shown in brown.  References quoted in 
the circos plot are listed in the Supplemental Information and detailed gene relationships are shown in 
Supplemental Data File 1.  
Figure 3.  Analysis of outcome for DESNT cancers identified by RF classification. (a-e) Kaplan-Meier PSA 
failure plots for the MSKCC (a), CancerMap (b), Stephenson (c), CamCap (d) and TCGA (e) datasets. For 
each dataset the cancers assigned to DESNT using the 20 gene RF classifier are compared to the remaining 
cancers. The number of cancers in each group is indicated in the bottom right corner of each plot. The 
number of cancers with PSA failure is indicated in parentheses.  Multivariate analyses were performed as 
described in the Methods for the MSKCC (f), CancerMap (g), Stephenson (h), CamCap (i) and TCGA (j) 
datasets. Pathological Stage covariates for MSKCC and Stephenson datasets did not meet the proportional 
hazards assumptions of the Cox model and have been modelled as time-dependent variables, as 
described in the Methods. 
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Figure 4. Comparison of RF-DESNT and non-RF-DESNT cancers in The Cancer Genome Atlas dataset. A 20 
gene random forest (RF) classifier was used to identify DESNT cancers (designated RF-DESNT cancers). The 
types of genetic alteration are shown for each gene (mutations, fusions, deletions, and overexpression). 
Clinical parameters including biochemical recurrence (BCR) are represented at the bottom together with 
groups for iCluster, methylation, somatic copy number alteration (SVNA) and mRNA[13]. When mutations 
and homozygous deletions for each gene were combined RF-DESNT cancers contained an excess of 
genetic alterations in BRCA2 (P = 0.021, χ² test) and TP53 (P = 0.0038), but after correcting for multiple 
testing these differences were not significant (P > 0.05).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1: Poor clinical outcome of patients with DESNT cancer 
 
For each dataset comparisons were made between PSA failures reported for DESNT and non-DESNT 
cancers.  LPD, Latent Process Decomposition; RF, Random Forest. For LPD the log-rank P-values represent 
the modal LPD run selected from the 100 independent LPD runs as described in the Methods. For 
multivariate analyses Gleason sum, PSA at diagnosis and Pathological Stage are included for all datasets 
with the exception of the TCGA dataset where only Gleason sum and Clinical Stage data were available.  
The full analyses are presented in Fig. 3 and Supplemental Fig. 3.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
Latent Process Decomposition 
Dataset Univariate p-value Multivariate p-value 
MSKCC 2.65×10−5 3.27×10−1 
CancerMap 2.98×10−8 3.66×10−3 
Stephenson 4.28×10−5 1.83×10−4 
CamCap 1.22×10−3 2.90×10−2 
Random Forest 
Dataset Univariate p-value Multivariate p-value 
MSKCC 1.85×10−3 6.05×10−1 
CancerMap 4.80×10−4 1.45×10−2 
Stephenson 1.75×10−4 4.56×10−4 
CamCap 1.61×10−5 1.31×10−4 
TCGA 5.41×10−4 2.59×10−2 
